Exclusive: Movement disorder biotech Vima steps onto scene with $60M

Kyle LaHucik

Biotech Correspondent

Since Bernard Ravina’s medical training in neurology in the 1990s, there have been few new therapies that treat a movement disorder known as dystonia. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Exclusive: Movement disorder biotech Vima steps onto scene with $60M

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

Large pharma companies spell out reasons why tariffs will harm US investments

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

DNA giant Illumina spawned an ecosystem of competitors and customers

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Ex­clu­sive: Move­ment dis­or­der biotech Vi­ma steps on­to scene with $60M

Biotech Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Exclusive: Movement disorder biotech Vima steps onto scene with $60M